HUM vs TARS · P/E 39, rev $129.66B vs rev $183.0M
Humana Inc (HUM) versus Tarsus Pharmaceuticals Inc (TARS) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
Latest reported HUM revenue for 2025-12-31 was $129.66B. Net income was $1.19B. Revenue was up 10.1% from 2024-12-31 to 2025-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported TARS revenue for 2024-12-31 was $183.0M. Net income was -$115.6M. Revenue was up 948.6% from 2023-12-31 to 2024-12-31. TARS currently screens at market cap $2.66B.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. TARS currently screens at market cap $2.66B.
Not investment advice. Open the HUM and TARS stock pages for the full models.
Not investment advice.